CCL2 and prostate carcinoma: Administration of monoclonal antibodies against CCL2 reduced recruitment of inflammatory monocytes and inhibited metastasis to lung in breast cancer, prostate cancer and it is currently being evaluated in ovarian cancer [116,117].